In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded.
0/5 보강
APA
Finsterer J (2025). In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded.. Internal medicine (Tokyo, Japan), 64(21), 3176. https://doi.org/10.2169/internalmedicine.5463-25
MLA
Finsterer J. "In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded.." Internal medicine (Tokyo, Japan), vol. 64, no. 21, 2025, pp. 3176.
PMID
40301043 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Before Diagnosing Encephalomyeloradiculoneuropathy, Infectious and Immune Encephalitis, Lymphomas, and Mitochondrial Disorders Must Be Ruled Out.
- Flaccid Lower Limb Paraparesis Despite Infiltration of the Spinal Cord by a Secondary Central Nervous System T-cell Non-Hodgkin Lymphoma With Syringomyelia: A Case Report.
- Death of a Child With Celiac Disease and Cerebral Bleeding Requires Extensive Post-Mortem Analysis to Clarify the Underlying Pathophysiology.
- Anti-recoverin Antibody-Associated Post-acute COVID Vaccination Syndrome After BNT162b2 in HLA-B27-Positive Spondylarthritis: A Case Report.
- Before Quadriparesis with Dysphagia can be Attributed to Covid-19, All Differential Causes Must Be Excluded.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
- Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).
- Immune checkpoint inhibitor-induced myocarditis with atrioventricular conduction abnormalities: a case report.